ResMed (ASX:RMD) reported its June quarter and full year results after the U. S. market closed on Friday morning. The company met consensus expectations for both revenue and earnings.     ResMed’s revenue rose nine per cent to US$1. 2 billion ($1. 85 billion) in the last quarter of fiscal 2024, taking quarterly dividends to US$0.

My prediction, for what it is worth, remains that small-caps should outperform their large-cap brethren, and conditions appear supportive for the share prices of innovative companies with pricing power and growth until the beginning of 2026.

The Aura Private Credit Income Fund (previously known as the Aura High Yield SME Fund) is celebrating its 7th anniversary today, 1 August 2024. We are delighted by the Fund’s performance since its inception.